Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rectal cancer: Real-World test of dostarlimab begins

NCT ID NCT07269249

Recruiting now Disease control Sponsor: National Cancer Institute, Naples Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 15 times

Summary

This study is tracking 50 people with a specific type of advanced rectal cancer (dMMR/MSI-H) who are getting the drug dostarlimab before surgery. The goal is to see how well the drug shrinks tumors and how safe it is in everyday medical practice, not just in a controlled research lab. Participants are being followed for up to several years to check for cancer return.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • ASL Napoli 1, Presidio Ospedaliero Ospedale del mare, Oncologia medica

    NOT_YET_RECRUITING

    Naples, 80131, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • IRCCS Fondazione G. Pascale, Unità Operativa Complessa Oncologia Addominale

    RECRUITING

    Naples, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED RECTAL CANCER (LARC)